CEO Andrew Simpson discusses how we’re one of the only companies leading the use of an AI-enabled EKG medical device to make it a far more valuable screening tool.

"Skip to content\nHome\nProducts\nClinical\nNews\nInvestors\nAbout Us\nContact Us\nINVEST NOW\nNEWS\nCEO Andrew Simpson discusses how we’re one of the only companies leading the use of an AI-enabled EKG medical device to make it a far more valuable screening tool.\nOctober 24, 2022\n\nCEO Andrew Simpson discusses how we’re one of the only companies leading the use of an AI-enabled EKG medical device to make it a far more valuable screening tool.\n\n$HSCS CEO Andrew Simpson discusses how we’re one of the only companies leading the use of an AI-enabled EKG medical device to make it a far more valuable screening tool. #AI #cardiotwitter Thanks @PlanetMicroCap @BobbyKKraft\n\nFull interview (7 min) → https://t.co/ESxOmnEbJ0 pic.twitter.com/rGLRCOZBV8\n\n— HeartSciences $HSCS #AI #ECG (@HeartSciences) October 24, 2022\n\nContacts\nMEDIA RELATIONS\n\nGene Gephart\nDirector of Marketing\n+1-682-244-2578 (US)\n\ngene.gephart@heartsciences.com\nINVESTOR CONTACT\n\nMark Komonoski – Partner\nIntegrous Communications\nDirect: 877-255-8483\n\ninvestorrelations@heartsciences.com\nwww.integcom.us\n